Natera receives FDA Breakthrough Device designation for its multi‑cancer early detection blood test
Natera announced that the U.S. Food and Drug Administration granted Breakthrough Device designation to its investigational multi‑cancer early detection (MCED) assay. The FDA reviewed performance data covering 12 cancer types, including sensitivity, specificity and cancer‑signal origin, before issuing the designation. The company said the status provides accelerated regulatory interaction but does not constitute marketing approval. Natera’s shares rose sharply on the news.
Why it matters
The designation gives Natera priority access to FDA feedback and a faster review pathway, which could shorten the time to a future marketing submission. The market reacted positively, with the stock gaining about 2% intraday and trading near its 52‑week high.
Key facts
- 1Natera received FDA Breakthrough Device Designation for its MCED blood test. tradingview.com
- 2The FDA evaluated data from 12 cancer types before granting the designation. finance.yahoo.com
- 3The agency assessed sensitivity, specificity and cancer‑signal origin performance. mugglehead.com
- 4Natera’s shares climbed to $403.62 after the announcement. mugglehead.com
- 5Shares were trading at $400.22, up 2.2% from the previous close. financialcontent.com
- 6Natera is up 74.9% year‑to‑date, near its 52‑week high of $425.64. financialcontent.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.